Pacific GeneTech
Focuses on developing and commercializing vaccines for the livestock industry through their proprietary Aegis platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
* | $10.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Pacific GeneTech, founded in 2009 and headquartered in Hong Kong, is a biologics company specializing in the development and commercialization of next-generation vaccines for animal health. The company operates in the global animal health market, focusing on unmet or underserved needs in food safety and animal health. Pacific GeneTech's proprietary Aegis vaccine platform forms the basis for its first-in-class or best-in-class recombinant vaccines, which provide broad protection against multiple strains and species of pathogens. The company partners with multinational and strong regional companies to commercialize its products through out-licensing partnerships, ensuring global distribution and manufacturing capabilities.
Pacific GeneTech's business model involves taking high-value research discoveries from the laboratory through development and regulatory processes to market. The company generates revenue through licensing agreements and joint ventures, such as its collaboration in Southeast Asia to manufacture and distribute the Hercules adjuvant delivery system. Additionally, Pacific GeneTech is working with partners to bring other innovative technologies into its development pipeline.
The company's clients include multinational corporations and regional companies in the animal health industry, as well as research institutions. By addressing critical gaps in the market, Pacific GeneTech aims to enhance food safety and animal health on a global scale.
Keywords: animal vaccines, recombinant platforms, food safety, animal health, Aegis platform, Hercules system, global distribution, licensing partnerships, unmet needs, biologics.